Mesothelioma Cancer Centers
Winship Cancer Institute of Emory University
Doctors Affiliated with this Treatment Facility
Winship Cancer Institute, which operates through Emory University Hospital, uses its state-of-the-art technology and research to treat patients diagnosed with mesothelioma. As Georgia’s only comprehensive cancer center, designated by the National Cancer Institute, the center provides groundbreaking therapies and treatments for patients.
Winship Cancer Institute is the only cancer center in Georgia to offer proton therapy as an emerging treatment method in radiation oncology. The therapy uses protons to treat mesothelioma tumors without damaging surrounding tissue. Immunotherapy, which shows promise for treating lung cancers, is also offered to mesothelioma patients at the center. In addition to non-surgical therapies and treatment, Winship also utilizes minimally invasive surgery to remove cancerous tissue or tumors from the lungs when necessary.
The institute provides a supportive oncology team, who can match patients with resources such as counseling, dietary needs, social services and can provide a nurse navigator for additional assistance. Winship’s clinical trial program allows patients to access novel treatment options that may not be found at other cancer centers. With five clinical trial locations throughout the Atlanta area, Winship has the ability to match patients with a clinical trial that caters to almost any type of cancer.
- Proton therapy
- Radiation therapy
- Minimally invasive surgery
- Targeted Therapy
- National Cancer Institute (NCI) Comprehensive Cancer Center
- Ranked No. 1 for cancer care in Georgia
- American College of Radiology Lung Cancer Screening Center
Mesothelioma Clinical Trials at Winship Cancer Institute of Emory University
The following clinical trials are in progress or actively recruiting participants at Winship Cancer Institute of Emory University:
Conditions: Solid Tumors; Triple-Negative Breast Cancer; Non Small Cell Lung Cancer; Renal Cell Carcinoma; Mesothelioma; Fumarate Hydratase (FH)-Deficient Tumors; Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST); Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors; Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations; Tumors Harboring Amplifications in the cMyc Gene Last Updated: July 18, 2018 Status: Active, not recruiting
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Conditions: Mesothelioma; Pleural Mesothelioma Last Updated: July 5, 2018 Status: Active, not recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette